---
title: "4D Molecular Therapeutics to present 2-year PRISM Phase 2b data for 4D-150 gene therapy in neovascular AMD at ASRS 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291328133.md"
description: "4D Molecular Therapeutics will present 2-year follow-up data from its PRISM Phase 2b trial of 4D-150 gene therapy for neovascular AMD at the ASRS 2026 meeting in Montreal. The July 18, 2026 podium update aims to inform expectations for 4D-150 as a longer-lasting treatment for wet age-related macular degeneration. 4D-150 is the company's lead Phase 3 program, with diabetic macular edema as a secondary target."
datetime: "2026-06-30T20:05:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291328133.md)
  - [en](https://longbridge.com/en/news/291328133.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291328133.md)
generator: "portal-rs"
---

# 4D Molecular Therapeutics to present 2-year PRISM Phase 2b data for 4D-150 gene therapy in neovascular AMD at ASRS 2026

-   4D Molecular Therapeutics set a July 18, 2026 podium update on 2-year follow-up results from its PRISM Phase 2b trial of 4D-150. \* The data will be presented in the future at the American Society of Retina Specialists annual meeting in Montreal. \* The readout is positioned to inform expectations for 4D-150 as a longer-lasting treatment approach for wet age-related macular degeneration. \* 4D-150 is the company’s lead program in Phase 3, with diabetic macular edema as a second target indication. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606301605PRIMZONEFULLFEED9754303) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [FDMT.US](https://longbridge.com/en/quote/FDMT.US.md)

## Related News & Research

- [4D Molecular Therapeutics posts corporate presentation highlighting AAV gene therapy pipeline led by 4D-150 for wet AMD, DME](https://longbridge.com/en/news/296635019.md)
- [4D Molecular Therapeutics CEO David Kirn disposes of common shares worth $1,068,651.63](https://longbridge.com/en/news/296648682.md)
- [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md)
- [Novogenia launches MGT Plus methylation genetic test in US market](https://longbridge.com/en/news/296876844.md)
- [Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301](https://longbridge.com/en/news/296321067.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**